PULMONARY CLINICAL TRIALS

The following clinical trials are either active and enrolling, upcoming or pending.  Contact information is also listed for patients interested in enrolling.

Titania

A Phase III, Multicenter, Randomized, Double – blind, Chronic –dosing, Parallel –group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations.  Click here for inclusion/exclusion criteria.

Principal Investigator:  Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta

Pillar

A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.  Click here for inclusion/exclusion criteria.

Principal Investigator:  Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta

ATYR 1923 C 005

Randomized, double-blind, placebo-controlled Proof-of-Conept (PoC) study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with Systemic Sclerosis (SSc)-related iterstitial Lung Disease (ILD) (SSc-ILD).  Click here for inclusion/exclusion criteria

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

Teton RIN-PF-302

An open-label extension study of inhaled Treprostinal in Subjects wtih Idiopathic Pulmonary Fibrosis.  Click here for inclusion/exclusion criteria

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

Genentech GB44496

A two-cohort, phase II, multicenter randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of Vixarelimab compared with placebo in patients with idiopathi pulmonary fibrosis and in patients with systemic sclerosis-associated interstitial lung.  Click here for inclusion/exclusion criteria

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

INSO18-055-003 (Insilico)

A phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmaokinetics, and efficay of INSO18-066 administered orally to subjects with Idiopathic Pulmonary Fibrosis (IPF).  

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

BMS-986278

A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. 

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

IFE-008 (Cumberland)

A randomized, double-bline, placebo-controlled phase II study with an open-label extension to determine the safety and efficacy of oral Ifetroban in patients with Idiopathic Pulmonary Fibrosis.  This study is pending.

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

DOMPE REP01222 (RESPIRATIO)

A phase II, proof-of-concept, randomized, double-blinded, placebo controlled, multicenter study to assess efficacy of Reparixin ass add-on therapy to standard of care in adult patients with ARDS (Acute Repiratory Distress Syndrome.  Click here for inclusions/exclusions criteria

Principal Investigator:  Tony Abdo, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

Biotest 996 ESsCAPE

A randomized, placebo-controlled, double-blind, multicenter, phase III trial to asess the efficacy and safety of Trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP).  Click here for inclusion/exclusion criteria

Principal Investigator:  Houssein Youness, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

VasoActive Therapy

To evaluate the impact of the vasoactive therapy upon patients with sepsis by following routinely monitored parameters of inflammation and organ failures scores to evaluate vasoactive therapy's efficacy in mitigating the impact of sepsis on the human body.  (This study is pending.)

Principal Investigator:  Brent Brown, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN